CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended A trucker in his late 70s who can't ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for ...

About 69,000 new cases and nearly 14,000 deaths are expected this year, according to the American Cancer Society.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...